Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
J Clin Pharmacol ; 63(4): 410-420, 2023 04.
Article in English | MEDLINE | ID: mdl-36394393

ABSTRACT

There is significant enterohepatic circulation (EHC) during the disposition of mycophenolic acid (MPA). The aim of this study was to elucidate factors influencing the EHC of MPA in Chinese adult renal allograft recipients. After 2 weeks of therapy with mycophenolate mofetil or enteric-coated mycophenolate sodium, blood samples were collected from 125 patients at 0 to 12 hours post-administration and MPA concentrations were determined. The influence of calcineurin inhibitors (CNIs) and genetic polymorphisms on MPA exposure and EHC was studied. The Shapley additive explanations method was used to estimate the impact of various factors on the area under the plasma drug concentration-time curve (AUC0-12h ) for MPA. An extreme gradient boosting (XGboost) machine learning-based model was established to predict AUC0-12h . Results showed that the dose-normalized AUC6-12h (dn-AUC6-12h ) of MPA was significantly lower in patients co-administered with cyclosporine (CsA) than in patients co-administered with tacrolimus (TAC) (P < .05). For patients co-administered with TAC, patients with ABCC2 C-24T CC or SLCO1B1 T521C TT genotypes had significantly higher values of dn-AUC6-12h (P < .05). Patients with SLCO1B3 334T/699G alleles had significantly lower dn-AUC6-12h values than homozygotes (P < .05). By introducing body weight, age, and EHC-related factors, including co-administered CNIs and genetic polymorphism of drug transporters, as covariates in the XGboost machine learning model, the prediction performance of AUC0-12h for MPA in Chinese adult renal allograft recipients can be improved.


Subject(s)
Kidney Transplantation , Mycophenolic Acid , Humans , Adult , Mycophenolic Acid/therapeutic use , Calcineurin Inhibitors , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/methods , East Asian People , Tacrolimus/pharmacology , Polymorphism, Genetic , Membrane Transport Proteins/genetics , Enterohepatic Circulation , Allografts , Area Under Curve , Liver-Specific Organic Anion Transporter 1/genetics
2.
Eur J Clin Pharmacol ; 78(8): 1261-1272, 2022 Aug.
Article in English | MEDLINE | ID: mdl-35536394

ABSTRACT

PURPOSE: Intracellular exposure of tacrolimus (TAC) may be a better marker of therapeutic effect than whole blood exposure. We aimed to evaluate the influence of genetic polymorphism on the pharmacokinetics of TAC in peripheral blood mononuclear cells (PBMCs) and develop limited sampling strategy (LSS) models to estimate the area under the curve (AUC0-12h) in the PBMC of Chinese renal transplant patients. METHODS: Ten blood samples of each of the 23 renal transplant patients were collected 0-12h after 14 (10-18) days of TAC administration. PBMCs were separated and quantified. The TAC level in PBMCs was determined, and pharmacokinetic parameters were estimated by noncompartmental study. The AUC0-12h of TAC in whole blood was estimated by Bayesian approach based on a population pharmacokinetic model established in 65 renal transplant patients. The influence of CYP3A5 and ABCB1 genotypes on exposure was estimated. By applying multiple stepwise linear regression analysis, LSS equations for TAC AUC0-12h in the PMBC of renal transplant patients were established, and the bias and precision of various equations were identified and compared. RESULTS: We found a modest correlation between TAC exposure in whole blood and PBMC (r2 = 0.5260). Patients with the CYP3A5 6986GG genotype had a higher AUC0-12h in PBMCs than those with the 6986 AA or GA genotype (P = 0.026). Conversely, patients with the ABCB1 3435TT genotype had a higher AUC0-12h in PBMC than those with the 3435 CC and CT genotypes (P = 0.046). LSS models with 1-4 blood time points were established (r2 = 0.570-0.989). The best model for predicting TAC AUC0-12h was C2-C4-C6-C10 (r2 = 0.989). The model with C0.5-C6 (r2 = 0.849) can be used for outpatients who need monitoring to be performed in a short period. CONCLUSIONS: The CYP3A5 and ABCB1 genotypes impact TAC exposure in PBMCs, which may further alter the effects of TAC. The LSS model consisting of 2-4 time points is an effective approach for estimating full TAC AUC0-12h in Chinese renal transplant patients. This approach may provide convenience and the possibility for clinical monitoring of TAC intracellular exposure.


Subject(s)
Cytochrome P-450 CYP3A , Immunosuppressive Agents , Kidney Transplantation , Tacrolimus , ATP Binding Cassette Transporter, Subfamily B/genetics , Area Under Curve , Bayes Theorem , Cytochrome P-450 CYP3A/genetics , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/pharmacokinetics , Leukocytes, Mononuclear , Tacrolimus/administration & dosage , Tacrolimus/pharmacokinetics , Transplant Recipients
3.
J Clin Pharmacol ; 61(3): 328-338, 2021 03.
Article in English | MEDLINE | ID: mdl-32926418

ABSTRACT

Valganciclovir (VGCV) is the prodrug of ganciclovir (GCV). The objective of this study was to establish a population pharmacokinetic model (PPK) of GCV to investigate the PK characteristics of GCV after administration of VGCV in adult Chinese renal allograft recipients. Seventy Chinese renal allograft recipients were given 450 mg (n = 41) or 900 mg (n = 29) VGCV daily. Blood samples were drawn 0-24 hours after 5 days' therapy, and GCV plasma levels were determined. The PPK model was constructed using nonlinear mixed-effects modeling, and the Bayesian estimation of AUC0-24h was constructed for an individual patient based on limited plasma samples. The PK of GCV was best described by a 2-compartment model with a first-order absorption process. The CL/F, V2 /F, Q/F, V3 /F, Ka , and lag time of GCV were 15.8 ± 0.71 L/h, 10.9 ± 2.38 L, 3.98 ± 0.40 L/h, 167 ± 44.0 L, 0.23 ± 0.0078 1/h, and 0.93 ± 0.017 hours, respectively. Clearance of creatinine was found to have a significant impact on the CL/F of GCV (P < .01). Sampling strategies consisted of plasma concentrations 0 and 2 and 0, 2, and 4 hours after VGCV administration were shown to be suitable for the estimation of the GCV AUC0-24h . The PPK model was acceptable and can describe the PK of GCV in Chinese renal transplant patients administered VGCV. The AUC0-24h of GCV in Chinese renal transplant patients can be calculated by a limited sampling strategy method.


Subject(s)
Ganciclovir/pharmacokinetics , Kidney Transplantation , Models, Biological , Valganciclovir/pharmacokinetics , Adolescent , Adult , Antiviral Agents/administration & dosage , Antiviral Agents/pharmacokinetics , Area Under Curve , Asian People , Bayes Theorem , Creatinine , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Nonlinear Dynamics , Valganciclovir/administration & dosage , Young Adult
4.
Ther Drug Monit ; 42(5): 686-694, 2020 10.
Article in English | MEDLINE | ID: mdl-32858576

ABSTRACT

BACKGROUND: Monitoring immunosuppressant levels, such as mycophenolic acid (MPA), cyclosporin A (CsA), and tacrolimus (TAC), in peripheral blood mononuclear cells (PBMCs) could be useful in organ transplant patients administered individualized therapy. The authors developed a liquid chromatography-tandem mass spectrometry assay technique to simultaneously determine immunosuppressant levels in PBMCs and assess their pharmacokinetics in Chinese renal allograft recipients. METHODS: PBMCs were isolated from the whole blood of 27 Chinese renal transplant patients using Ficoll-Paque Plus solution, and cell number was determined; acetonitrile treatment for protein precipitation, and gradient elution was performed on an Agilent Eclipse XDB-C18 column (3.5 µm, 2.1 × 100 mm) with mobile phase: water and methanol (containing 2 mM ammonium formate); flow rate: 0.3 mL·min. RESULTS: The calibration curves of MPA, CsA, and TAC had a linear range (ng·mL): 0.098-39.2 (r = 0.9987), 0.255-102 (r = 0.9969), and 0.028-11.2 (r = 0.9993), respectively. The extraction effects, matrix effects, and mean relative recovery of these immunosuppressants were 70.4%-93.2%, 72.7%-96.5%, and 90.1%-112.4%, respectively. The within-day and between-day coefficients of variation were <15%. The AUC0-12 of MPA in PBMCs correlated well with those in plasma. The level of MPA, CsA, and TAC in PBMCs might be more stable during dosing interval. CONCLUSIONS: The derived liquid chromatography-tandem mass spectrometry assay is suitable for simultaneously monitoring different immunosuppressants in PBMCs. Pharmacokinetic of MPA, CsA, and TAC displayed considerable interindividual variability. Intracellular monitoring of immunosuppressants may facilitate individualized therapy for renal allograft recipients.


Subject(s)
Chromatography, Liquid/methods , Immunosuppressive Agents/blood , Immunosuppressive Agents/pharmacokinetics , Leukocytes, Mononuclear/chemistry , Tandem Mass Spectrometry/methods , Adolescent , Asian People , Cyclosporine/blood , Cyclosporine/pharmacokinetics , Cyclosporine/therapeutic use , Drug Monitoring/methods , Female , Humans , Immunosuppressive Agents/therapeutic use , Kidney/metabolism , Kidney Transplantation/methods , Male , Mycophenolic Acid/blood , Mycophenolic Acid/pharmacokinetics , Mycophenolic Acid/therapeutic use , Tacrolimus/blood , Tacrolimus/pharmacokinetics , Tacrolimus/therapeutic use , Transplant Recipients
5.
Phytother Res ; 33(4): 1019-1026, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30746789

ABSTRACT

Epigallocatechin-3-gallate (EGCG) and caffeine in tea exert anti-obesity effects and induces nonalcoholic fatty liver disease (NAFLD) amelioration. However, previous studies usually performed a high-dose EGCG administration, whereas the insecurity was arisen in recent researches. In this study, we treated obese rats with an elaborate dose-40 mg/kg EGCG, 20 mg/kg caffeine, and the coadministration of them as low dose, which were similar to the daily intake; 160 mg/kg EGCG as high dose, which was the maximum safe dose had touched the contentious edge. The results suggested that the coadministration of EGCG and caffeine exerted more remarkable function on suppressing body weight gain, reducing white adipose tissue weight and decreasing the energy intake than single use. This may be due to the variation in serum lipid profile, oxidative stress, and adipose-derived and inflammatory cytokines. The pathological micrographs showed long-term high-fat diets caused severe NAFLD, but it was ameliorated at different levels by all of the administrations. In summary, low dose of EGCG or caffeine only showed a mild effect of anti-obesity and NAFLD amelioration. The coadministration of them could exert a superior curative effect as well as high dose EGCG but no anxiety regarding safety.


Subject(s)
Caffeine/administration & dosage , Catechin/analogs & derivatives , Non-alcoholic Fatty Liver Disease/drug therapy , Obesity/drug therapy , Animals , Body Weight/drug effects , Catechin/administration & dosage , Diet, High-Fat , Dose-Response Relationship, Drug , Drug Therapy, Combination , Male , Non-alcoholic Fatty Liver Disease/complications , Non-alcoholic Fatty Liver Disease/pathology , Obesity/complications , Obesity/pathology , Oxidative Stress/drug effects , Rats , Rats, Sprague-Dawley , Tea/chemistry
6.
Eur J Clin Pharmacol ; 75(5): 677-686, 2019 May.
Article in English | MEDLINE | ID: mdl-30643927

ABSTRACT

OBJECTIVES: Valganciclovir (VGCV) treatment is recommended for the prevention of cytomegalovirus (CMV) infection in renal allograft recipients. The aim of the present study is to investigate the pharmacokinetic characteristics of ganciclovir (GCV) after administration of VGCV in Chinese adult renal allograft recipients and estimate the exposure to GCV using limited sampling strategy (LSS). METHODS: Forty Chinese renal allograft recipients were given 450 mg or 900 mg VGCV daily. Blood samples were drawn before treatment and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 h after 5 days of VGCV therapy, and the plasma concentrations of VGCV and GCV were determined using a liquid chromatography-mass spectrometry assay. The major pharmacokinetic parameters for GCV and VGCV were determined using a noncompartmental assay. Multiple stepwise linear regression analysis was conducted to establish a model equation for the estimation of the GCV AUC0-24 h in Chinese patients using LSS. RESULTS: In the 450 and 900 mg groups, the Cmax for VGCV was 0.2 ± 0.10 and 0.4 ± 0.16 mg/L, respectively; the Cmax for GCV was 4.2 ± 1.1 and 8.6 ± 1.6 mg/L, respectively; and the AUC0-24 h for GCV was 28.4 ± 8.4 and 60.7 ± 17.5 mg·h/L, respectively. For the establishment of LSS models, 40 patients were divided into the training group (n = 24) and validation group (n = 16). The model equations used for the calculation of AUC0-24 h for GCV were established in the training group by using multiple linear regression assay. Equations including AUC = 8.1 + 29.7 × C0 + 5.7 × C4 (r2 = 0.91) and AUC = - 0.4 + 11.0 × C0 + 2.1 × C2 + 13.7 × C8 (r2 = 0.98) were acceptable. The %MPE and %MAPE values obtained from the validation group for the two model equations were 5.89 ± 14.5% and 12.1 ± 9.53%, and - 1.30 ± 4.40% and 3.28 ± 3.11%, respectively. CONCLUSIONS: The LSS models that included C0 and C4 or C0, C2, and C8 in the estimation of AUC0-24 h for GCV had favorable performance and can be used for therapeutic drug monitoring in the prevention of CMV infection using VGCV in Chinese renal allograft recipients.


Subject(s)
Blood Specimen Collection/methods , Ganciclovir/blood , Kidney Transplantation , Valganciclovir/blood , Adolescent , Adult , Antiviral Agents/blood , Antiviral Agents/pharmacokinetics , Antiviral Agents/therapeutic use , Area Under Curve , Asian People , Cytomegalovirus Infections/metabolism , Cytomegalovirus Infections/prevention & control , Drug Monitoring/methods , Female , Ganciclovir/pharmacokinetics , Ganciclovir/therapeutic use , Humans , Immunosuppressive Agents/adverse effects , Male , Middle Aged , Transplantation, Homologous , Valganciclovir/pharmacokinetics , Valganciclovir/therapeutic use
7.
J Clin Pharmacol ; 59(4): 578-589, 2019 04.
Article in English | MEDLINE | ID: mdl-30537048

ABSTRACT

The aim of the present study is to establish a population pharmacokinetic (PPK) model of mycophenolic acid (MPA) and limited sampling strategy models for the estimation of MPA exposure in Chinese adult renal allograft recipients following oral administration of enteric coated mycophenolate sodium (EC-MPS). A total of 74 sets of full pharmacokinetic profiles and 47 sets of MPA-sparing samples were collected from 102 renal transplant recipients who received oral EC-MPS. The MPA concentration was determined by an enzyme-multiplied immunoassay technique, and the pathophysiologic data were recorded. The PPK model was constructed using nonlinear mixed-effects modeling, and the limited sampling strategy models for MPA were established by using multiple regression analysis and the maximum a posteriori Bayesian assay based on 2 to 4 sampling time points following EC-MPS administration. The pharmacokinetics of MPA were best described by a 2-compartment model with a first-order absorption process and a lag time of absorption. The clearance of MPA was 12.3 ± 1.14 L/h. Comedicating with cyclosporine A was found to have a significant impact on the clearance/bioavailability of MPA (P < .01). Sampling strategies consisted of plasma concentration at 1.5, 2, 4 (C1.5-C2-C4) hours and 1.5, 2, 4, 6 (C1.5-C2-C4-C6) hours after EC-MPS administration were shown to be suitable for the estimation of the MPA area under the concentration-time curve in these patients. The PPK model was acceptable and can describe the pharmacokinetics of MPA in Chinese renal transplant recipients administered EC-MPS. The area under the concentration-time curve of MPA in Chinese renal transplant recipients could be estimated through a limited sampling strategy method, based on which individualized immunosuppressive regimens could be designed.


Subject(s)
Immunosuppressive Agents/pharmacokinetics , Kidney Transplantation , Models, Biological , Mycophenolic Acid/pharmacokinetics , Adult , Aged , Area Under Curve , Asian People , Bayes Theorem , Biological Availability , Cyclosporine/administration & dosage , Drug Therapy, Combination , Female , Humans , Immunosuppressive Agents/administration & dosage , Male , Middle Aged , Mycophenolic Acid/administration & dosage , Tablets, Enteric-Coated , Young Adult
9.
Sichuan Da Xue Xue Bao Yi Xue Ban ; 41(2): 235-8, 2010 Mar.
Article in Chinese | MEDLINE | ID: mdl-20506642

ABSTRACT

OBJECTIVE: To study the expression of IL-17 in blood and nasal tissue of allergic rhinitis and nasal polyps, and to investigate the possible mechanism of IL-17 in the progress of allergic rhinitis and nasal polyps. METHODS: There were 41 patients enrolled, including the patients with allergic rhinitis, nasal polyps and deviated nasal septum. The blood and nasal mucosa tissue or nasal polyps were collected in all the patients. The expression of IL-17 was measured by the methods of ELISA and immunohistochemisty, and the number of eosinophils and IL-17 positive cells was measured. RESULTS: The IL-17 expression of nasal polyps was significantly elevated in the blood and nasal tissue, which was obviously correlated with the number of eosinophils infiltrated in nasal tissue. However, for the patients with allergic rhinitis, there was only apparent expression of IL-17 in nasal mucosa. CONCLUSION: IL-17 plays an important role in the development of nasal polyps, but for allergic rhinitis, it needs further study as an potential important aspect of the pathogenesis.


Subject(s)
Interleukin-17/metabolism , Nasal Polyps/metabolism , Rhinitis, Allergic, Perennial/metabolism , Adolescent , Adult , Eosinophils/immunology , Female , Humans , Interleukin-17/blood , Leukocyte Count , Male , Middle Aged , Young Adult
10.
Sichuan Da Xue Xue Bao Yi Xue Ban ; 39(3): 489-91, 2008 May.
Article in Chinese | MEDLINE | ID: mdl-18575350

ABSTRACT

OBJECTIVE: To explore an effective microsurgical approach to the treatment of cranionasal tumors. METHODS: A retrospective review of 18 micro-neurosurgical patients with cranionasal tumors (June 2005 to June 2007) was undertaken. RESULTS: All of the 18 patients were treated with subfrontal approaches in combination with transnasal endoscopy. Tumors were resected in the stage-one operations (14 were totally resected and 4 were subtotally resected). The anterior skull bases were reconstructed. Transient CSF rhinorrhea was found in two cases. All of the patients experienced good recoveries, with no operative death. The follow up after 5 to 29 months revealed that only four patients had tumor recurrence. Three patients lost in the follow up. CONCLUSION: Subfrontal microsurgical operation combined with transnasal endoscopy is an effective approach to the treatment of cranionasal tumors. It enables high total resection rate and has low complications.


Subject(s)
Nose Neoplasms/surgery , Skull Base Neoplasms/surgery , Adolescent , Adult , Aged , Endoscopy/methods , Female , Humans , Magnetic Resonance Imaging , Male , Microsurgery/methods , Middle Aged , Neurosurgical Procedures/methods , Retrospective Studies , Skull Base/surgery , Tomography, X-Ray Computed , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...